<DOC>
	<DOCNO>NCT02713776</DOCNO>
	<brief_summary>During rectal complex digestive surgery multiple digestive resection anastomosis , creation enterostomy common procedure . In France , estimate 20000 patient ileostomy 16000 new digestive stoma form year approximately 30 % enterostomy . Enterostomy might sometimes give high-output control usual medical treatment ( e.g loperamide ± codeine ) expose patient important hydro-electrolytic loss lead risk dehydration , electrolyte abnormality acute renal failure . This risk imply parenteral correction may extend hospital stay delay home return . Somatostatin analogue ( octreotide , lanreotide pasireotide ) could reduce digestive secretion decrease digestive peristalsis . Nevertheless , somatostatin analogue routinely use treatment patient high-output enterostomy efficacy indication ( off-label ) test small case series . Pasireotide ( SOM230 , SIGNIFOR® ) currently indicate treatment patient Cushing 's disease surgery option surgery fail . As efficacity pasireotide patient high-output enterostomy refractory usual medical treatment associate oral fluid restriction never demonstrate , need perform pilot , double-blind , randomize , placebo-controlled trial evaluate impact reduction effluent volume .</brief_summary>
	<brief_title>Reduction Pasireotide Effluent Volume High-output Enterostomy Patients Refractory Usual Medical Treatment</brief_title>
	<detailed_description />
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Male Female patient ≥ 18 year old ; Patients underwent intestinal surgery enterostomy repair three week precede inclusion ; Patients highoutput ileostomy jejunostomy &gt; 1000 ml/24h ; Patients failure treatment combine oral fluid restriction loperamide ( 8 capsules/24h ) +/ codeine syrup ( 10 mg x 3/24h ) 5 day ; Patients give write informed consent participate study ; Patients affiliate social insurance regime . Male Female patient &lt; 18 year old ; Patients give write informed consent participate study ; Patients receive somatostatin analogue month inclusion ; Patients symptomatic cholelithiasis acute chronic pancreatitis ; Patients uncontrolled diabetes ( HbA1c ( glycated hemoglobin ) &gt; 8 % ) ; Patients hypothyroid adequate replacement therapy ; Patients congestive heart failure ( NYHA ( New York Heart Association ) Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , advanced heart block history clinically significant bradycardia acute myocardial infarction within 6 month precede randomization ; Patients history syncope family history idiopathic sudden death ; Patients screen baseline ( predose ) : QT interval correct heart rate use Fridericia 's correction ( QTcF ) QTcF &gt; 450 msec ( male ) , QTcF &gt; 460 msec ( female ) ( QT interval correct heart rate use Fridericia 's correction ) ; Patients correct hypokalaemia and/or hypomagnesaemia ; Patients liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis , patient alanine transaminase/aspartate transaminase ( ALT/AST ) &gt; 2 x Upper Limit Normal ( ULN ) , serum bilirubin &gt; 2 x ULN ; Patients ChildPugh C cirrhosis ; Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control ; Patients active malignant disease within last five year ( exception basal cell carcinoma carcinoma situ cervix ) ; Patients abnormal coagulation ( PT and/or APTT elevate 30 % normal limit ) patient receive anticoagulant affect PT ( prothrombin time ) activate partial thromboplastin time ( APTT ) ; Patients know hypersensitivity somatostatin analogue component pasireotide LAR ; Patients guardianship ; Patients nonaffiliated social insurance regime .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>High-Output Enterostomy</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>Somatostatin Analogues</keyword>
</DOC>